Genzyme and Isis Begin Second Phase 3 Trial Of ... (us organisms. Isis is a jointowner of Re...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen

Date:8/6/2008

us organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

Genzyme Safe Harbor Statement

This press release contains forward-looking statements, including without limitation, statements concerning mipomersen's safety and benefits for patients with high cholesterol, the development plan for mipomersen and FDA's requirements for its approval. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: the timing of further discussions with FDA regarding the approval of mipomersen; the timing and content of submissions to and decisions made by the FDA relating to mipomersen; further analysis of clinical trial data; the results of other studies; the actual efficacy and safety of mipomersen; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date and Genzyme undertakes no obligation to update or revise the statements.

Isis Safe Harbor Statement

This press release includes forward-looking statements regarding Isis' collaboration with Genzyme Corporation, its financial and business developme
'/>"/>

SOURCE Genzyme Corp.; Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Genzyme and Isis Complete Licensing of Mipomersen
2. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
3. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
4. Genzyme Announces Presentation of New Positive Data on Carticel(R)
5. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
6. Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
7. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
8. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
9. Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
10. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases

Post Your Comments:

Breaking Medicine Technology:Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 2 Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 3 BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in China's National Insurance Catalog 2 BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in China's National Insurance Catalog 3 Elsevier Selects BrainTrack Directory as Supplier of College Data 2 Elsevier Selects BrainTrack Directory as Supplier of College Data 3 Elsevier Selects BrainTrack Directory as Supplier of College Data 4 GSK Improving Performance to Continue in Second Half 52381 1 Carefx Implements Fusionfx at Fletcher Allen Health Care to Improve Anywhere Anytime Access to Crucial Patient Information 52377 1 Carefx Implements Fusionfx at Fletcher Allen Health Care to Improve Anywhere Anytime Access to Crucial Patient Information 52377 2 Carefx Implements Fusionfx at Fletcher Allen Health Care to Improve Anywhere Anytime Access to Crucial Patient Information 52377 3 AMERIGROUP Public Policy Institute Black Leadership Forum Inc Convene Summit to Examine Preterm Birth Policy Solutions 52373 1 AMERIGROUP Public Policy Institute Black Leadership Forum Inc Convene Summit to Examine Preterm Birth Policy Solutions 52373 2 AMERIGROUP Public Policy Institute Black Leadership Forum Inc Convene Summit to Examine Preterm Birth Policy Solutions 52373 3

[0] Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology [0] BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in China's National Insurance Catalog [0] Elsevier Selects BrainTrack Directory as Supplier of College Data

Other Medicine Technology:AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2,Data for Ozarelix, in BPH at Annual AUA Meeting 2 AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2,Data for Ozarelix, in BPH at Annual AUA Meeting 3 AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2,Data for Ozarelix, in BPH at Annual AUA Meeting 4 AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2,Data for Ozarelix, in BPH at Annual AUA Meeting 5 MIV Therapeutics Announces Renowned Researcher to Detail Milestone,Pre-Clinical Results at Prominent International Conference EuroPCR,2007 2 MIV Therapeutics Announces Renowned Researcher to Detail Milestone,Pre-Clinical Results at Prominent International Conference EuroPCR,2007 3 MIV Therapeutics Announces Renowned Researcher to Detail Milestone,Pre-Clinical Results at Prominent International Conference EuroPCR,2007 4

AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2,Data for Ozarelix, in BPH at Annual AUA Meeting MIV Therapeutics Announces Renowned Researcher to Detail Milestone,Pre-Clinical Results at Prominent International Conference EuroPCR,2007

[0] Soy Beneficial for Breast Cancer Survivors: Study [1] Researchers Use New Techniques to Assess PTSD [0] Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries)[1] Patient Safety Organization (PSO) Participation: What Every Provider Needs to Know [1] Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends)

Other Medicine News:Health News:Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex 2 Health News:Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex 3 Health News:Stigma Keeps Teens From Depression Treatment 2 Health News:The Ottawa Hospital Transforms Procurement and Spend Management with the Oracle(R) E-Business Suite 2 Health News:The Ottawa Hospital Transforms Procurement and Spend Management with the Oracle(R) E-Business Suite 3 Health News:The Ottawa Hospital Transforms Procurement and Spend Management with the Oracle(R) E-Business Suite 4 Health News:Gyminee Raises 525K and Relaunches as DailyBurn 2 Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 2 Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 3 Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 4 Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 5 Health News:Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making 2 Health News:Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making 3

Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex Stigma Keeps Teens From Depression Treatment The Ottawa Hospital Transforms Procurement and Spend Management with the Oracle(R) E-Business Suite Gyminee Raises 525K and Relaunches as DailyBurn Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking?Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making

Medicine Products:

STA STACHROM PROTEIN C ASSERACHROM PROTEIN C STA ROTACHROM HEPARIN 4 STA DEFICIENT X

Genzyme and Isis Begin Second Phase 3 Trial Of ...(us organisms. Isis is a jointowner of Re...),Health